Urovant Chief Executive Keith Katkin

Urovant Chief Executive Keith Katkin

Irvine-based Urovant Sciences Inc. is seeking $150 million via the public markets to extend clinical trials of therapies to treat urologic conditions.

Its lead drug candidate Vibegron is in an international phase 3 trial for overactive bladders; a second phase 3 trial of men with overactive bladder as a result of benign prostatic hyperplasia, or age-related prostate gland enlargement; and a phase 2 trial treating pain associated with irritable bowel syndrome.

Urovant is a unit of Swiss pharmaceutical company Roviant Sciences Ltd., which owns a family of companies that develops therapeutics in areas including women’s health, neurology and dermatology